Chris Hollowood, Freeline chairman (Syncona)

Free­line nabs $120M, eyes IPO as its gene ther­a­py comes in­to fo­cus

Free­line Ther­a­peu­tics has land­ed an­oth­er mega-round to back its gene ther­a­py ef­forts and, on the same morn­ing of the an­nounce­ment, in­di­cat­ed that they could yet …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.